NASDAQ:SRDX - SurModics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$71.95 +0.15 (+0.21 %)
(As of 08/21/2018 10:36 AM ET)
Previous Close$71.75
Today's Range$70.85 - $71.95
52-Week Range$25.00 - $74.10
Volume209 shs
Average Volume133,949 shs
Market Capitalization$980.67 million
P/E Ratio139.12
Dividend YieldN/A
Beta0.61
SurModics logoSurmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and Ireland. It operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. The Vitro Diagnostics segment provides stabilization products, substrates, antigens, and surface coatings to diagnostics customers; and manufactures or sells components for in vitro diagnostic immunoassay and molecular tests, as well as surface coatings to the diagnostic, biomedical research, and life science markets. SurModics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Receive SRDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:SRDX
CUSIP86887310
Phone952-500-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio2.50
Quick Ratio2.37

Price-To-Earnings

Trailing P/E Ratio139.12
Forward P/E Ratio167.33
P/E Growth17.08

Sales & Book Value

Annual Sales$73.11 million
Price / Sales13.14
Cash Flow$0.9408 per share
Price / Cash76.48
Book Value$8.41 per share
Price / Book8.56

Profitability

EPS (Most Recent Fiscal Year)$0.51
Net Income$3.92 million
Net Margins-2.94%
Return on Equity7.53%
Return on Assets5.63%

Miscellaneous

Employees257
Outstanding Shares13,350,000
Market Cap$980.67 million

SurModics (NASDAQ:SRDX) Frequently Asked Questions

What is SurModics' stock symbol?

SurModics trades on the NASDAQ under the ticker symbol "SRDX."

How were SurModics' earnings last quarter?

SurModics, Inc. (NASDAQ:SRDX) announced its earnings results on Monday, August, 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.51. The firm earned $22.23 million during the quarter, compared to analysts' expectations of $19.81 million. SurModics had a positive return on equity of 7.53% and a negative net margin of 2.94%. View SurModics' Earnings History.

When is SurModics' next earnings date?

SurModics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for SurModics.

What price target have analysts set for SRDX?

4 Wall Street analysts have issued 12-month price objectives for SurModics' shares. Their forecasts range from $73.00 to $90.00. On average, they anticipate SurModics' stock price to reach $79.00 in the next year. This suggests a possible upside of 10.5% from the stock's current price. View Analyst Price Targets for SurModics.

What is the consensus analysts' recommendation for SurModics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SurModics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SurModics.

What are Wall Street analysts saying about SurModics stock?

Here are some recent quotes from research analysts about SurModics stock:
  • 1. Needham & Company LLC analysts commented, "SRDX beat consensus F3Q18 revenue and EPS. Management raised its FY18 revenue and adjusted EPS guidance. Revenue growth improved to 24.9% in in F2Q18. SRDX’s 2Q18 gross margin was down 210 bps Y/Y and its non-GAAP operating margin was up 100 bps Y/Y. We expect new products (.014" and .018” balloon dilation catheters and Telemark microcatheter) and deferred revenue associated with the ABT agreement milestones to drive accelerating revenue growth and additional upside to consensus estimates and we reiterate our Buy rating." (8/6/2018)
  • 2. According to Zacks Investment Research, "Surmodics outperformed its industry in a year's time. The company’s solid efforts to improve its research and development stature have been a key growth driver. Further, solid performance in the In Vitro Diagnostics segment, which gained grounds on the back of strong growth and stabilization across BioFX, microarray and antigen product sales holds promise. Surmodics issued a solid guidance for fiscal 2018. On the flipside, the company witnessed significantly high operating losses. Product sales declined owing to shipment issues, particularly in the Medical Device segment. Further, foreign-exchange woes related to the Creagh Medical buyout have been a major dampener. Surmodics’ drug-coated balloons face stiff competition in niche space. The company’s margins are expected to be under pressure, due to expenses in the Irish facility infrastructure and lower Medical-Device product gross margins." (7/3/2018)
  • 3. Barrington Research analysts commented, "We are now modeling adjusted FY/18 adjusted EPS of $(0.02) and revenue of $78.4 million. DCB: Patient enrollment for the company’s TRANSCEND pivotal clinical trial continues and about half of U.S.-based clinical sites have now been activated. As a reminder, the trial to treat peripheral artery disease in the upper leg will be randomized and is expected to include 446 patients at up to 60 clinical sites in the U.S. and 18 sites in Europe. It will feature a head-to-head comparison with a competitor’s already commercialized drug-coated balloon product 510(k) products: Surmodics has now received FDA approvals for its first three 510(k) products (two balloon catheters and a microcatheter). Management remains hopeful that it will enter into partnership for all three products over the next two to four quarters Recommendation: We are maintaining our OUTPERFORM investment rating on SRDX shares. Our new price target is $43, up from our previous $38." (5/3/2018)

Who are some of SurModics' key competitors?

Who are SurModics' key executives?

SurModics' management team includes the folowing people:
  • Mr. Gary R. Maharaj, CEO, Pres & Director (Age 55)
  • Mr. Bryan K. Phillips, Sr. VP of Legal & HR, Gen. Counsel and Corp. Sec. (Age 47)
  • Mr. Charles W. Olson, Sr. VP of Commercial & Bus. Devel. - Medical Devices (Age 54)
  • Mr. Thomas A. Greaney, Chief Operating Officer of Medical Devices (Age 52)
  • Mr. Timothy J. Arens, VP of Corp. Devel. & Strategy, Interim VP of Fin. and CFO (Age 51)

Has SurModics been receiving favorable news coverage?

News headlines about SRDX stock have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. SurModics earned a news and rumor sentiment score of 0.14 on Accern's scale. They also gave news stories about the company an impact score of 43.02 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for SurModics.

Who are SurModics' major shareholders?

SurModics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (15.51%), Trigran Investments Inc. (8.57%), Renaissance Technologies LLC (7.66%), Dimensional Fund Advisors LP (4.77%), Royce & Associates LP (2.92%) and Teton Advisors Inc. (1.98%). Company insiders that own SurModics stock include Bryan K Phillips, Charles W Olson, Gary R Maharaj, Jose H Bedoya, Joseph J Stich, Susan E Knight and Timothy J Arens. View Institutional Ownership Trends for SurModics.

Which major investors are selling SurModics stock?

SRDX stock was sold by a variety of institutional investors in the last quarter, including Trigran Investments Inc., Millennium Management LLC, Segall Bryant & Hamill LLC, Gabelli Funds LLC, Rice Hall James & Associates LLC, Gamco Investors INC. ET AL, EAM Investors LLC and Foundry Partners LLC. Company insiders that have sold SurModics company stock in the last year include Bryan K Phillips, Charles W Olson, Gary R Maharaj, Jose H Bedoya, Joseph J Stich, Susan E Knight and Timothy J Arens. View Insider Buying and Selling for SurModics.

Which major investors are buying SurModics stock?

SRDX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Federated Investors Inc. PA, Acadian Asset Management LLC, ClariVest Asset Management LLC, Royce & Associates LP, Renaissance Technologies LLC, Mackay Shields LLC and Spark Investment Management LLC. View Insider Buying and Selling for SurModics.

How do I buy shares of SurModics?

Shares of SRDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SurModics' stock price today?

One share of SRDX stock can currently be purchased for approximately $71.50.

How big of a company is SurModics?

SurModics has a market capitalization of $980.67 million and generates $73.11 million in revenue each year. The company earns $3.92 million in net income (profit) each year or $0.51 on an earnings per share basis. SurModics employs 257 workers across the globe.

How can I contact SurModics?

SurModics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The company can be reached via phone at 952-500-7000 or via email at [email protected]


MarketBeat Community Rating for SurModics (NASDAQ SRDX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  222 (Vote Outperform)
Underperform Votes:  185 (Vote Underperform)
Total Votes:  407
MarketBeat's community ratings are surveys of what our community members think about SurModics and other stocks. Vote "Outperform" if you believe SRDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel